Prevalence of sarcopenia in COPD patients using AWGS criteria among Asian populations: a systematic review and meta-analysis Authors: Yogesh Murugan, Vaibhavkumar N Shrivastav, Hari Krishna Akurathi Published: 2026 ABSTRACT AbstractBackgroundSarcopenia is a critical comorbidity in chronic obstructive pulmonary disease (COPD), yet prevalence estimates in Asian populations using standardized Asian Working Group for Sarcopenia (AWGS) criteria remain uncertain. This review aimed to determine pooled sarcopenia prevalence in Asian COPD patients using AWGS criteria, compare AWGS-2014 versus AWGS-2019 estimates, and identify associated risk factors.MethodsWe systematically searched eight databases from inception to December 2024 for studies reporting sarcopenia prevalence in Asian COPD patients using AWGS-2014 or AWGS-2019 criteria. Pooled prevalence with 95% confidence intervals (CI) was calculated using random-effects meta-analysis with Freeman-Tukey double arcsine transformation. Quality was assessed using the Newcastle-Ottawa Scale. Subgroup analyses compared AWGS versions, and pooled odds ratios were calculated to examine risk factors. The review was registered with PROSPERO (CRD420251274827).ResultsTen studies encompassing 2,371 COPD patients from five Asian countries were included. Eight studies used AWGS-2019, and two used AWGS-2014. Overall, the pooled sarcopenia prevalence was 31% (95% CI: 22–41%) with substantial heterogeneity (I²=89.9%). Individual study prevalence ranged from 9.5% to 52.5%. Subgroup analysis revealed no significant difference between AWGS-2014 (30%, 95% CI: 24–38%) and AWGS-2019 (31%, 95% CI: 22–42%) criteria (p = 0.916). All studies demonstrated high methodological quality (NOS scores: 8–10/10). Three independent risk factors were identified: older age (OR: 1.05 per year, 95% CI: 1.03–1.07), low BMI < 18.5 kg/m² (OR: 3.12, 95% CI: 1.98–4.92), and severe COPD stages 3–4 (OR: 2.74, 95% CI: 1.89–3.97).ConclusionsApproximately one-third of Asian COPD patients have sarcopenia, with comparable prevalence between AWGS versions. Findings support routine screening in high-risk subgroups and integrated care pathways addressing respiratory and musculoskeletal manifestations.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12890-026-04452-3.Keywords: Sarcopenia, COPD, Asian Working Group for Sarcopenia, Meta-analysis, Asia Introduction Chronic obstructive pulmonary disease (COPD) represents a major global health challenge, characterized by progressive airflow limitation and persistent respiratory symptoms. According to the World Health Organization, COPD is the third leading cause of death worldwide, accounting for approximately 3.23 million deaths annually, with the highest burden observed in low- and middle-income countries [1]. The Global Burden of Disease Study 2019 estimated that COPD affected 212.3 million individuals globally, with prevalence rates demonstrating substantial geographic variation, particularly across Asian populations where rapid urbanization, air pollution, and biomass fuel exposure contribute to disease burden [2]. Beyond respiratory impairment, COPD is increasingly recognized as a systemic disease with extrapulmonary manifestations that significantly impact patient outcomes, functional capacity, and quality of life [3]. Sarcopenia, defined as the progressive loss of skeletal muscle mass, strength, and physical performance [4], has emerged as a critical comorbidity in COPD patients, contributing to disability, increased hospitalization rates, and mortality [5, 6]. The Asian Working Group for Sarcopenia (AWGS) established standardized diagnostic criteria specifically tailored for Asian populations, recognizing ethnic differences in body composition, muscle mass distribution, and anthropometric characteristics compared to Western populations [7]. The original AWGS consensus published in 2014 provided the first unified diagnostic framework for Asian populations, incorporating assessments of muscle mass, muscle strength, and physical performance with population-specific cut-off values [7]. Subsequently, the updated AWGS-2019 consensus refined the diagnostic algorithm based on accumulated evidence from diverse Asian cohorts, adjusting cut-off values for handgrip strength and appendicular skeletal muscle mass while maintaining the core diagnostic framework. Importantly, AWGS-2019 also introduced a population-level screening algorithm recommending the use of SARC-F or SARC-CalF questionnaires to identify high-risk individuals prior to confirmatory assessment and incorporated the five-time chair stand test as an alternative measure of physical performance alongside gait speed [8].The pathophysiological mechanisms linking COPD and sarcopenia are complex and multifactorial, involving chronic systemic inflammation, oxidative stress, hormonal dysregulation, physical inactivity, nutritional depletion, and hypoxemia-induced metabolic alterations [9]. Elevated circulating levels of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP), promote muscle protein degradation through activation of the ubiquitin-proteasome pathway and suppression of protein synthesis, accelerating muscle wasting in COPD patients [10]. Furthermore, corticosteroid therapy, frequently prescribed for COPD management, exacerbates muscle atrophy by inducing catabolic processes and impairing muscle regeneration capacity [11]. The clinical implications of sarcopenia in COPD are profound and well-documented. Sarcopenic COPD patients demonstrate significantly impaired exercise capacity, reduced health-related quality of life, increased risk of acute exacerbations, prolonged hospital stays, higher healthcare costs, and elevated mortality risk compared to non-sarcopenic counterparts [5]. Jones et al. (2015) demonstrated that skeletal muscle dysfunction independently predicted mortality in COPD patients, even after adjusting for lung function parameters and other confounding variables [6]. Moreover, sarcopenia contributes to respiratory muscle weakness, impaired cough effectiveness, and increased susceptibility to respiratory infections, creating a vicious cycle of progressive functional decline [12]. Despite growing recognition of sarcopenia’s clinical significance in COPD, reported prevalence estimates demonstrate considerable heterogeneity across studies, ranging from less than 10% to over 60% depending on the diagnostic criteria employed, study population characteristics, disease severity distribution, and geographic location [13]. This variability poses challenges for clinical decision-making, resource allocation, and development of targeted intervention strategies. The coexistence of AWGS-2014 and AWGS-2019 criteria in recent literature adds another layer of complexity, as differences in cut-off values between versions may influence prevalence estimates and complicate cross-study comparisons. Earlier meta-analyses examining sarcopenia prevalence in COPD have primarily included Western populations or utilized heterogeneous diagnostic criteria, limiting their applicability to Asian populations where distinct body composition phenotypes and genetic backgrounds may influence sarcopenia manifestation and progression [13]. Given the substantial burden of COPD in Asian countries and the evolution of AWGS diagnostic criteria, there is an urgent need to synthesize available evidence on sarcopenia prevalence in Asian COPD populations using standardized AWGS assessment methods. Notably, AWGS-2019 introduced stricter cut-off values for handgrip strength and appendicular skeletal muscle mass index compared to AWGS-2014, which generally results in lower reported sarcopenia prevalence in general older populations. Whether this reduction also applies to COPD patients who may have more severe, disease-driven muscle atrophy that exceeds both thresholds remains unknown, representing a critical knowledge gap. To our knowledge, no systematic review has specifically examined whether AWGS-2014 and AWGS-2019 criteria yield comparable prevalence estimates in COPD populations, nor comprehensively synthesized evidence across Asian countries using these population-specific diagnostic standards. Therefore, this systematic review and meta-analysis aimed to: (1) determine the pooled prevalence of sarcopenia among COPD patients in Asian populations using AWGS diagnostic criteria (both 2014 and 2019 versions); (2) compare prevalence estimates between AWGS-2014 and AWGS-2019 criteria to assess diagnostic equivalence in COPD populations; (3) evaluate potential sources of heterogeneity through comprehensive subgroup analyses; (4) assess the quality of available evidence; and (5) identify risk factors associated with sarcopenia in this population. The findings will inform clinical practice guidelines, screening strategies, and future research directions for managing sarcopenia in Asian COPD populations. Methods Study design and registration This systematic review and meta-analysis was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines [14]. The review protocol was prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO) to ensure transparency and minimize reporting bias (CRD420251274827). The study design adhered to established methodological standards for prevalence meta-analyses, incorporating rigorous search strategies, explicit eligibility criteria, systematic data extraction procedures, and comprehensive quality assessment [15]. Literature search strategy A comprehensive systematic literature search was conducted across eight electronic databases including PubMed/MEDLINE, Embase, Web of Science, Scopus, and the Cochrane Library from inception to December 2024 [16]. Additionally, regional Asian databases including China National Knowledge Infrastructure (CNKI), WanFang Database, and KoreaMed were searched to capture studies published in local languages and minimize language bias. The search strategy combined Medical Subject Headings (MeSH) terms and free-text keywords related to three core concepts: (1) chronic obstructive pulmonary disease (“COPD” OR “chronic obstructive pulmonary disease” OR “chronic airflow obstruction” OR “emphysema” OR “chronic bronchitis”); (2) sarcopenia (“sarcopenia” OR “muscle wasting” OR “muscle loss” OR “skeletal muscle mass” OR “appendicular skeletal muscle mass” OR “muscle atrophy”); and (3) Asian populations (“Asia” OR “Asian” OR specific country names including “China” OR “Japan” OR “Korea” OR “India” OR “Thailand” OR “Malaysia” OR “Singapore” OR “Indonesia” OR “Philippines” OR “Vietnam”). The search strategy was developed in consultation with a medical librarian and adapted appropriately for each database with consideration of database-specific indexing systems and controlled vocabularies. No language restrictions were applied during the initial search phase. Reference lists of included studies and relevant systematic reviews were manually screened to identify additional eligible studies through backward citation searching [17]. Eligibility criteria Studies were included if they met the following criteria: (1) Population: adult patients (≥ 18 years) with clinically diagnosed COPD according to established spirometric criteria (post-bronchodilator FEV₁/FVC < 0.70) as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. It is acknowledged that COPD diagnosis in individuals under 40 years requires particular caution, as spirometric obstruction in this age group may reflect developmental airway disease, asthma, or other conditions rather than classic COPD; the age distribution of included study participants was therefore carefully extracted and reported. During data extraction, the method of COPD diagnosis was recorded for each study. Studies that did not explicitly confirm use of post-bronchodilator spirometry (e.g., those relying on pre-bronchodilator spirometry, ICD codes, or self-report) were retained but flagged as a potential source of bias and noted in the quality assessment domain for exposure ascertainment [18]; (2) Exposure: studies conducted exclusively in Asian populations or reporting separate data for Asian subgroups; (3) Outcome: sarcopenia diagnosed using the Asian Working Group for Sarcopenia consensus criteria (either AWGS-2014 or AWGS-2019)(detailed version is mentioned in Supplementary Table-1), incorporating assessments of muscle strength (handgrip strength), muscle quantity (appendicular skeletal muscle mass by DXA or BIA), and physical performance (gait speed or chair stand test) [7, 8]; (4) Study design: cross-sectional studies, cohort studies (baseline prevalence data), or case-control studies reporting sarcopenia prevalence; and (5) sufficient data to calculate prevalence estimates with confidence intervals (number of sarcopenia cases and total sample size). Regarding BIA-based muscle mass assessment, information on measurement standardization (e.g., fasting state, abstinence from vigorous exercise for ≥ 12 h, no alcohol consumption prior to measurement, as recommended by AWGS-2019) was systematically extracted during data extraction to assess protocol quality and as a potential source of heterogeneity. Studies were excluded if they: (1) enrolled exclusively pediatric populations (< 18 years); (2) utilized sarcopenia diagnostic criteria other than AWGS-2014 or AWGS-2019 (e.g., EWGSOP, IWGS, FNIH criteria); (3) included mixed populations without separate reporting for Asian patients; (4) were conference abstracts, case reports, case series, editorials, commentaries, or reviews without original data; (5) duplicate publications of the same cohort without additional data; or (6) lacked sufficient information to extract prevalence data despite attempts to contact authors. Study selection process All identified records were imported into EndNote X9 reference management software (Clarivate Analytics, Philadelphia, PA, USA), and duplicate entries were systematically removed using both automated and manual methods [19]. Two independent reviewers (VS and HK) screened titles and abstracts against predetermined eligibility criteria, classifying records as potentially eligible, clearly ineligible, or uncertain. Full-text articles were retrieved for all potentially eligible and uncertain records. The same reviewers independently assessed full-text articles for inclusion, with disagreements resolved through discussion or consultation with a third senior reviewer (YM) when consensus could not be reached. The study selection process was documented using a PRISMA flow diagram (supplementary figure-1), detailing the number of records identified, screened, assessed, excluded with reasons, and ultimately included in the qualitative synthesis and quantitative meta-analysis [14]. Data extraction A standardized, pilot-tested data extraction form was developed in Microsoft Excel to ensure consistency and completeness of extracted information. Two reviewers independently extracted data from each included study, with discrepancies resolved through consensus discussion. The following information was systematically extracted: (1) Study characteristics: first author, publication year, country of origin, study design (cross-sectional, cohort, case-control), study setting (hospital-based, community-based, or both), sample size; (2) Population characteristics: mean age, age range, sex distribution, COPD severity distribution (GOLD stages), mean FEV₁% predicted, smoking history; (3) Sarcopenia assessment: diagnostic criteria version (AWGS-2014 or AWGS-2019), muscle mass measurement method (DXA, BIA), handgrip strength assessment protocol, physical performance measurement (gait speed, chair stand test, SPPB); (4) Outcome data: number of participants with sarcopenia, total sample size, prevalence estimate with 95% confidence intervals if reported; and (5) Additional data: risk factors associated with sarcopenia (age, BMI, COPD severity), study limitations, funding sources. When studies reported sarcopenia prevalence stratified by subgroups (e.g., COPD severity, sex, setting), data for all relevant subgroups were extracted separately. For studies reporting only unadjusted prevalence data, we extracted raw numbers and calculated prevalence estimates with exact binomial 95% confidence intervals [20]; all of the variables of included studies were mentioned in Table 1. Table 1Characteristics of Studies Included in the Review on Sarcopenia in COPDFirst authorYearCountryStudy designStudy settingSample sizeAge (mean)AWGS criteriaParticipants with sarcopenia (n)Prevalence (%)Zhai [21]2024ChinaCross-sectionalHospital30372.96AWGS 201912240.2Limpawattana [22]2018ThailandCross-sectionalHospital12170.0AWGS 20142924.0Wu [23]2023ChinaCohort (baseline)Hospital12076.7AWGS 20196352.5Kim [24]2024South KoreaCross-sectionalHospital6374.7AWGS 201969.5Wang [25]2023ChinaCross-sectionalHospital19867.1AWGS 20195427.3Choi [26]2023South KoreaCohort (baseline)Hospital8068.3AWGS 20191620Lee [27]2016South KoreaCross-sectionalCommunity85850.0AWGS 201428633.3Wang [28]2025ChinaCross-sectionalboth41469.7AWGS 20199522.9Mohamad Zani [29]2025MalaysiaCross-sectionalHospital10365.1AWGS 20193736Yogesh M [30]2023IndiaCross-sectionalHospital11156AWGS 20195852 Characteristics of Studies Included in the Review on Sarcopenia in COPD Quality assessment and risk of bias The methodological quality of included studies was independently assessed by two reviewers using an adapted version of the Newcastle-Ottawa Scale (NOS) for cross-sectional and cohort studies. The adaptation involved adding one criterion to the standard 9-point NOS (Selection: 4, Comparability: 2, Outcome: 3) by incorporating an additional Selection item (S5) evaluating adequacy of sample size justification or power calculation, yielding a maximum possible score of 10 points. This adapted scale was applied consistently to both cross-sectional and cohort study designs, and is presented in full in Supplementary Table-1 [31]. The NOS evaluates three domains: (1) Selection of study groups (representativeness of sample, sample size justification, non-respondent characteristics, ascertainment of exposure); (2) Comparability of groups (control for important confounding factors in design or analysis); and (3) Ascertainment of outcome (assessment of sarcopenia using validated methods, appropriateness of statistical analysis). Studies were awarded stars for each criterion met, with a maximum possible score of 10 points. Quality scores were categorized as high (8–10 points), moderate (5–7 points), or low (0–4 points). Additionally, we assessed risk of bias across individual domains including selection bias, measurement bias, attrition bias, and confounding bias. Publication bias was evaluated through visual inspection of funnel plot asymmetry and quantitative assessment using Egger’s regression test [32] and Begg’s rank correlation test [33]. Statistical analysis and meta-analysis All statistical analyses were performed using R version 4.3.2 (R Foundation for Statistical Computing, Vienna, Austria) with the meta package (version 6.5-0) specifically designed for meta-analysis of prevalence data [34]. The pooled prevalence of sarcopenia with corresponding 95% confidence intervals was estimated using the metaprop function, which implements specialized variance-stabilizing transformations appropriate for proportions. Specifically, we employed the Freeman-Tukey double arcsine transformation to stabilize variances and accommodate studies reporting zero events or 100% prevalence [35]. Between-study heterogeneity was quantified using the I² statistic, which represents the percentage of total variation across studies attributable to true heterogeneity rather than sampling error (I² values of 25%, 50%, and 75% were interpreted as low, moderate, and high heterogeneity, respectively) [36], Cochran’s Q statistic with corresponding p-value, and the between-study variance (τ²) estimated using the restricted maximum likelihood (REML) method [37]. Given the anticipated clinical and methodological diversity across included studies, we employed a random-effects meta-analysis model using the DerSimonian-Laird method with Hartung-Knapp adjustment for confidence interval estimation, which provides more conservative inference in the presence of heterogeneity and small numbers of studies [38]. Results were presented as pooled prevalence estimates with 95% confidence intervals and displayed using forest plots with individual study estimates, weights, and the overall pooled estimate represented by a diamond. Subgroup and meta-regression analyses Pre-specified subgroup analyses were conducted to explore potential sources of heterogeneity and assess whether sarcopenia prevalence varied across clinically relevant subgroups. Subgroup analyses were performed for the following characteristics: (1) AWGS diagnostic criteria version (AWGS-2014 versus AWGS-2019); (2) geographic region and country; (3) muscle mass assessment method (DXA versus BIA); (4) study design (cross-sectional versus cohort studies); (5) study setting (hospital-based versus community-based versus mixed); (6) sample size categories (< 100, 100–200, > 200 participants); and (7) publication year (before 2020 versus 2020 and after). Within-subgroup pooled prevalence estimates and between-subgroup heterogeneity were calculated, with statistical significance of subgroup differences assessed using Cochran’s Q test for heterogeneity between subgroups [39]. In addition, when a sufficient number of studies (> 10) were available, univariate meta-regression analyses were planned to examine associations between study-level covariates (mean age, sample size, publication year) and prevalence estimates. However, as only ten studies were included, this pre-planned meta-regression was not carried out due to insufficient statistical power. Instead, for investigation of patient-level risk factors, odds ratios (ORs) reported in the included studies were extracted and pooled using random-effects models as described in the Analysis of Risk Factors section below; this represents a conventional meta-analysis of comparative data and should be distinguished from meta-regression [40]. Sensitivity analysis The robustness of pooled prevalence estimates was evaluated through leave-one-out sensitivity analysis, in which the meta-analysis was repeated 10 times, each time excluding one study systematically [41]. This approach assessed whether any single study exerted disproportionate influence on the overall pooled estimate. Additionally, we conducted sensitivity analyses by: (1) excluding studies with high risk of bias (NOS score < 8); (2) excluding studies with small sample sizes (< 50 participants); and (3) repeating the analysis using alternative transformation methods (logit transformation versus arcsine transformation) and pooling models (common-effect versus random-effects) to assess the impact of methodological choices on findings. Analysis of risk factors For studies reporting associations between potential risk factors and sarcopenia prevalence in COPD patients, we extracted odds ratios (ORs) or calculated them from reported data when possible. Pooled ORs with 95% confidence intervals were calculated for common risk factors (older age, low BMI, severe COPD) using random-effects models with the metafor package [42]. Heterogeneity was assessed using I² statistics and τ². When different studies reported risk factors using different scales or categorizations, we attempted to harmonize the data or performed separate analyses for comparable subsets of studies. It should be noted that the number of studies contributing to each risk factor pool was small (3–4 studies per factor), and included studies varied in their adjustment for confounding factors; no two studies controlled for an identical set of confounders. Accordingly, the pooled ORs should be interpreted as unadjusted associations and findings interpreted with caution given the limited statistical power and potential for residual confounding. Sensitivity analyses and formal heterogeneity testing for each risk factor are reported in Supplementary Table-3. Publication bias assessment Publication bias was assessed through multiple approaches. Funnel plot asymmetry was visually inspected by plotting study precision (standard error) against effect size (prevalence) [43]. Egger’s weighted regression test was used to statistically detect funnel plot asymmetry, with p-value < 0.10 considered indicative of potential publication bias [32]. Additionally, Begg’s rank correlation test was performed as a complementary assessment [33]. We acknowledged that for prevalence meta-analyses with fewer than 10 studies, statistical tests for publication bias have limited power and results should be interpreted cautiously. Given this limitation, a trim-and-fill analysis was also performed as a supplementary validation approach to assess the potential impact of unpublished or missing studies on the pooled estimate. The conclusions from these tests are considered exploratory rather than definitive. All statistical tests were two-tailed, with p-values < 0.05 considered statistically significant unless otherwise specified. Results Study selection The systematic database search identified a total of 1,247 records across eight databases. After removal of 312 duplicates, 935 records were screened at the title and abstract stage, of which 891 were excluded as clearly ineligible. Full-text assessment was performed for 44 potentially eligible studies, and 34 were excluded with reasons (including use of non-AWGS diagnostic criteria, non-Asian populations, insufficient data, and duplicate cohorts). Ultimately, ten studies met all eligibility criteria and were included in the quantitative meta-analysis. The complete study identification and selection process is documented in the PRISMA flow diagram (Supplementary Fig. 1). Study characteristics The characteristics of the ten included studies are summarized in Table 1. Publication years ranged from 2016 to 2025. Studies were conducted across five Asian countries: China (n = 4 studies), South Korea (n = 2), Thailand (n = 1), Malaysia (n = 1), and India (n = 1), with one additional study involving a mixed Asian cohort. The majority were hospital-based (n = 8), with two community-based studies. Eight studies used AWGS-2019 criteria and two used AWGS-2014. Muscle mass was measured by DXA in four studies and by BIA in six studies. Sample sizes ranged from 63 (kim 2024) to 858 participants (Lee 2016), with a total of 2,371 COPD patients across all studies. Meta-analysis results The forest plot presents the comprehensive meta-analysis of sarcopenia prevalence across ten studies encompassing 2,371 COPD patients from multiple Asian countries. Individual study prevalence estimates ranged from 0.095 (9.5%; 95% CI: 0.04–0.20) in kim 2024 (South Korea) to 0.53 (95% CI: 0.43–0.62) in Wu 2023 (China), demonstrating considerable variability across populations. The random effects model produced a pooled prevalence of 0.31 (95% CI: 0.22–0.41). Statistical heterogeneity was substantial, with I² = 89.9% (τ² = 0.3489, p < 0.0001), indicating that nearly 90% of the total variation in prevalence estimates was attributable to true between-study differences rather than sampling error. The wide confidence intervals for individual studies reflect varying sample sizes, ranging from 63 participants (kim 2024) to 858 participants (Lee 2016), with the total pooled sample size of 2,371 patients. Other notable prevalence estimates included Zhai 2024 at 0.40 (95% CI: 0.35–0.46), Yogesh 2023 at 0.52 (95% CI: 0.43–0.62), Mohamad Zani 2025 at 0.36 (95% CI: 0.27–0.46), and Lee 2016 at 0.33 (95% CI: 0.30–0.37). The forest plot visualization demonstrates that most study-specific confidence intervals overlap with the pooled estimate diamond, although notable outliers exist at both extremes, particularly kim 2024 at the lower end and Wu 2023 and Yogesh 2023 at the upper end, contributing to the observed heterogeneity (Fig. 1). Overall Pooled Prevalence of Sarcopenia in COPD Patients The subgroup analysis stratified studies according to the Asian Working Group for Sarcopenia (AWGS) diagnostic criteria version used for sarcopenia assessment. Eight studies employing AWGS-2019 criteria encompassed 1,392 participants and yielded a pooled prevalence of 0.32 (95% CI: 0.30–0.35) under the common effect model and 0.31 (95% CI: 0.22–0.42) under the random effects model, with substantial heterogeneity (I² = 91.7%, τ² = 0.4459, p < 0.0001). In contrast, two studies utilizing AWGS-2014 criteria included 979 participants and demonstrated a pooled prevalence of 0.32 (95% CI: 0.29–0.35) under the common effect model and 0.30 (95% CI: 0.24–0.38) under the random effects model, with moderate heterogeneity (I² = 76.2%, τ² = 0.0191, p = 0.0403). The overall pooled prevalence across all ten studies was 0.32 (95% CI: 0.30–0.34) under the common effect model and 0.31 (95% CI: 0.23–0.40) under the random effects model, with high heterogeneity (I² = 89.9%, τ² = 0.3489, p < 0.0001). Tests for subgroup differences revealed no statistically significant difference between AWGS versions (common effect: χ²₁ = 0.01, p = 0.9087; random effects: χ²₁ = 0.01, p = 0.9162), suggesting that the choice of AWGS criteria version did not substantially impact sarcopenia prevalence estimates in COPD patients (Fig. 2). Subgroup Analysis of Sarcopenia Prevalence by AWGS Diagnostic Criteria Version The leave-one-out sensitivity analysis demonstrates the robustness of the pooled prevalence estimate by systematically excluding each study one at a time and recalculating the combined effect. The forest plot displays ten iterations, each representing the meta-analysis results with one study omitted. The pooled prevalence estimates when omitting individual studies ranged from 0.29 (95% CI: 0.21–0.38) when excluding Wu 2023 or Yogesh 2023 to 0.33 (95% CI: 0.25–0.43) when excluding kim 2024, with corresponding I² values ranging from 88.2% to 91.1%. The final random effects model yielded a pooled prevalence of 0.31 (95% CI: 0.22–0.41) with Tau² = 0.3489, Tau = 0.5907, and I² = 89.9%, indicating substantial heterogeneity. The narrow range of prevalence estimates (0.29–0.33) across all iterations confirms the stability of the meta-analytic findings, demonstrating that no single study disproportionately influenced the overall pooled estimate. This consistency supports the reliability of the reported sarcopenia prevalence in COPD patients despite the presence of considerable between-study heterogeneity (Fig 3). Leave-One-Out Sensitivity Analysis for Pooled Sarcopenia Prevalence Six additional subgroup analyses were pre-specified in the protocol (geographic region/country, muscle mass assessment method [DXA vs. BIA], study design, study setting, sample size categories, and publication year). However, given the limited number of included studies (n = 10), with several subgroups comprising fewer than three studies, these analyses could not be conducted with adequate statistical reliability. This represents a planned deviation from the registered protocol and is acknowledged as a limitation. Exploratory observations regarding geographic variation and measurement methodology are discussed in the Discussion section. Figure 4 presents a funnel plot with trim-and-fill analysis to assess publication bias in the pooled sarcopenia prevalence estimate across ten Asian COPD studies (N = 2,371). Each filled circle (●) represents one observed study, plotted by its Freeman–Tukey transformed prevalence (θ) on the x-axis against its standard error (SE) on the inverted y-axis, where values near zero indicate larger, more precise studies. The shaded triangular region represents the 95% pseudo-confidence region around the original pooled estimate. The dashed vertical line denotes the original pooled prevalence of 31.5% (θ = 1.1916; 95% CI: 25.0–38.3%; I² = 90.9%, τ² = 0.0468), and the solid vertical line denotes the trim-and-fill adjusted estimate of 24.9% (θ = 0.9709; 95% CI: 16.9–33.9%; I² = 95.8%, τ² = 0.1153). Trim-and-fill analysis (Duval & Tweedie, 2000; L0 estimator) identified k₀ = 2 potentially missing studies, represented as open diamonds (◇; k1 and k2), which are mirror reflections of Wu 2023 and Yogesh 2023 the two highest-prevalence studies — imputed on the left side of the funnel. The 6.6%-point reduction in the adjusted estimate suggests a potential modest over-estimation in the primary analysis, though this should be interpreted cautiously given the small number of studies (n = 10). Complementary formal tests showed no statistically significant funnel plot asymmetry (Egger’s test: t = 0.54, p = 0.596; Begg’s test: z = 0.37, p = 0.712), and the original estimate of approximately 31% remains broadly robust. All estimates are based on Freeman–Tukey double arcsine transformation with DerSimonian–Laird random-effects pooling. Funnel plot with trim and fill analysis Supplementary Table- 2 Title: Quality Assessment of Included Studies Using the Newcastle-Ottawa Scale (NOS). The quality assessment table presents the methodological evaluation of ten included studies using the adapted Newcastle-Ottawa Scale (NOS) for cross-sectional studies. The NOS assessment comprises three domains: Selection (S1–S5), Comparability (C1–C2), and Outcome (O1–O3), with a maximum possible score of 10 points. Selection criteria evaluated representativeness of the sample (S1), sample size adequacy (S2), non-respondent characteristics (S3), ascertainment of exposure (S4), and control for potential confounders (S5). Comparability criteria assessed whether studies controlled for important confounding factors in the design or analysis (C1) and whether additional relevant factors were controlled (C2). Outcome criteria evaluated the assessment method for sarcopenia (O1), appropriateness of statistical tests (O2), and adequacy of outcome ascertainment (O3). Quality scores ranged from 8 to 10 points, indicating generally high methodological rigour across all included studies. Two studies (Zhai 2024 and Choi 2023) achieved the maximum score of 10/10, meeting all NOS criteria. Three studies (Limpawattana 2018, kim 2024, and Mohamad Zani 2025) scored 9/10, each lacking one comparability criterion (C2). Five studies (Wu 2023, Wang 2023, Lee 2016, Wang 2025, and Yogesh 2023) scored 8/10, missing S5 and comparability criterion C2. All studies consistently satisfied selection criteria S1–S4 and all outcome criteria (O1–O3), demonstrating adequate sample representativeness, appropriate statistical methods, and valid sarcopenia assessment procedures. The most common methodological limitation was inadequate control for confounding variables in the comparability domain, although this did not substantially compromise the overall quality of the evidence base. The consistently high NOS scores support the validity and reliability of the included studies’ findings regarding sarcopenia prevalence in COPD patients. Supplementary Table 3: Risk Factors Associated with Sarcopenia in COPD Patients: Pooled Odds Ratios from Meta-Analysis. This table presents the pooled odds ratios (ORs) with 95% confidence intervals (CIs) for risk factors associated with sarcopenia in chronic obstructive pulmonary disease (COPD) patients, derived from random-effects meta-analysis. Three key risk factors demonstrated statistically significant associations with sarcopenia prevalence. Older age showed a dose-response relationship with sarcopenia risk, with each additional year of age associated with a 5% increased odds of sarcopenia (pooled OR: 1.05 per year; 95% CI: 1.03–1.07; I² = 42%; 4 studies). Low body mass index (BMI < 18.5 kg/m²) emerged as a strong predictor of sarcopenia, with underweight COPD patients demonstrating more than three-fold higher odds of sarcopenia compared to those with normal or higher BMI (pooled OR: 3.12; 95% CI: 1.98–4.92; I² = 36%; 3 studies). Severe COPD, defined as GOLD stages 3 and 4 (FEV₁ <50% predicted), was independently associated with sarcopenia, with patients in advanced disease stages having nearly three times the odds of sarcopenia compared to those with mild-to-moderate disease (pooled OR: 2.74; 95% CI: 1.89–3.97; I² = 51%; 3 studies). Moderate heterogeneity was observed across studies for severe COPD (I² = 51%), while heterogeneity was lower for older age (I² = 42%) and low BMI (I² = 36%), indicating relatively consistent effects across different populations and settings. These findings identify three modifiable and non-modifiable risk factors that could inform targeted screening strategies and preventive interventions for sarcopenia in COPD populations. The dose-response relationship with age suggests that sarcopenia screening should be prioritized in elderly COPD patients, while the strong associations with low BMI and severe disease severity highlight the importance of nutritional assessment and intensive management in advanced COPD stages. Discussion Principal findings This systematic review and meta-analysis represents the first comprehensive synthesis of sarcopenia prevalence in COPD patients across Asian populations using standardized AWGS diagnostic criteria, incorporating both AWGS-2014 and AWGS-2019 versions. Our analysis of 10 studies encompassing 2,371 COPD patients from five Asian countries (China, South Korea, Thailand, Malaysia, and India) revealed an overall pooled sarcopenia prevalence of 31% (95% CI: 22–41%). Eight studies employing AWGS-2019 criteria (n = 1,392 patients) yielded a pooled prevalence of 31% (95% CI: 22–42%), while two studies using AWGS-2014 criteria (n = 979 patients) reported a pooled prevalence of 30% (95% CI: 24–38%). Subgroup analysis revealed no statistically significant difference between these diagnostic versions (p = 0.916), suggesting diagnostic equivalence in COPD populations. Individual study estimates demonstrated substantial heterogeneity, ranging from 9.5% to 52.5%, with considerable between-study variability (I² = 89.9%, τ² = 0.3489, p < 0.0001). Despite this heterogeneity, leave-one-out sensitivity analysis confirmed the robustness of our findings, with pooled estimates remaining stable across all iterations (range: 29–33%). Quality assessment using the Newcastle-Ottawa Scale demonstrated consistently high methodological rigor across included studies (scores 8–10/10), supporting the validity of our conclusions. Our meta-analysis identified three significant risk factors independently associated with sarcopenia in COPD patients: advancing age (pooled OR: 1.05 per year, 95% CI: 1.03–1.07), low body mass index < 18.5 kg/m² (pooled OR: 3.12, 95% CI: 1.98–4.92), and severe COPD stages 3–4 (pooled OR: 2.74, 95% CI: 1.89–3.97). Comparison with previous literature Our pooled prevalence estimate of 31% aligns closely with previous meta-analyses examining sarcopenia in COPD populations, though direct comparisons are complicated by differences in diagnostic criteria and population characteristics. Sepúlveda-Loyola et al. (2020) reported a pooled sarcopenia prevalence of 27.5% (95% CI: 19.9–35.1%) across 22 studies using diverse diagnostic criteria (EWGSOP, IWGS, AWGS, and others), predominantly in Western populations [13]. The similarity of our estimate to this global meta-analysis suggests that sarcopenia burden in Asian COPD populations is comparable to Western cohorts when standardized diagnostic criteria are applied, contrary to earlier hypotheses that ethnic differences in body composition might substantially influence prevalence estimates [44]. A more recent systematic review focusing on sarcopenia across various chronic diseases reported similar findings, with COPD patients demonstrating prevalence rates between 25 and 40% depending on diagnostic criteria and population characteristics [45]. Notably, our findings demonstrate substantially lower heterogeneity in effect estimates compared to previous meta-analyses that incorporated multiple diagnostic systems, supporting the critical importance of diagnostic standardization in prevalence meta-analyses [46]. The individual study prevalence rates in our meta-analysis (9.5–52.5%) encompass the wide range reported in previous literature, reflecting genuine population heterogeneity rather than methodological inconsistency. Studies reporting lower prevalence estimates predominantly enrolled younger, community-dwelling [47], while higher estimates (40–52.5%) were observed in hospital-based cohorts with older age distributions and more severe airflow limitation [22]. This pattern aligns with established disease-severity gradients observed in Western COPD populations, where sarcopenia prevalence increases progressively from approximately 15% in GOLD stage 1 to over 40% in GOLD stages 3–4 [48]. Diagnostic criteria comparison: AWGS-2014 versus AWGS-2019 A key finding of our meta-analysis is the lack of significant difference in sarcopenia prevalence between AWGS-2014 and AWGS-2019 criteria in COPD populations (30% versus 31%, p = 0.916). This diagnostic equivalence is particularly noteworthy given that AWGS-2019 generally identifies fewer sarcopenia cases in general elderly populations, with studies reporting approximately 20–30% lower prevalence when applying the updated criteria [49]. The AWGS-2019 revision introduced more stringent cut-off values for handgrip strength (males: <28 kg; females: <18 kg) and appendicular skeletal muscle mass index by height² (males: <7.0 kg/m²; females: <5.7 kg/m²) compared to AWGS-2014 thresholds, with the intention of improving diagnostic specificity and reducing false-positive identification [8]. The comparable prevalence estimates between criteria versions in COPD populations may reflect several potential mechanisms, though these remain speculative and require prospective confirmation. First, COPD-related muscle wasting is often severe and multifactorial, driven by systemic inflammation, hypoxemia, physical inactivity, nutritional depletion, and medication effects [50]. It is hypothesized that individuals with sarcopenia in this disease context may demonstrate profound muscle deficits that exceed diagnostic thresholds under both criteria versions. Second, the COPD population may exhibit different muscle loss patterns compared to general aging, with disproportionate loss of muscle strength relative to mass (dynapenic sarcopenia) or selective atrophy of specific muscle groups (particularly lower extremity and respiratory muscles) [10]. These disease-specific characteristics may render the population less sensitive to the specific cut-off adjustments implemented in AWGS-2019, though this hypothesis warrants direct testing in prospective studies. Third, the limited number of AWGS-2014 studies (n = 2) in our meta-analysis precludes definitive conclusions, and the confidence intervals for both subgroups overlap substantially, indicating uncertainty in the true difference. From a practical standpoint, this finding has important implications for clinical screening programs and research synthesis. The diagnostic equivalence suggests that either AWGS version can be appropriately used for sarcopenia screening in COPD populations without substantially over- or under-estimating prevalence. This enhances the comparability of studies published during the transition period between criteria versions and supports pooling of evidence across both diagnostic standards in future meta-analyses focused on COPD. However, for longitudinal studies tracking sarcopenia incidence or intervention effects, consistent use of a single criteria version is still recommended to minimize measurement variability [51]. Future research should prospectively compare AWGS-2014 and AWGS-2019 within the same COPD cohort to definitively establish diagnostic concordance and identify any subgroups where criteria choice may influence classification. Sources of heterogeneity The substantial heterogeneity observed in our meta-analysis (I² = 89.9%) warrants detailed consideration of potential contributing factors beyond AWGS criteria version. Geographic variation emerged as a potential source of heterogeneity, though the limited number of studies from most countries precluded definitive statistical testing. Chinese studies demonstrated considerable internal variability (prevalence 22.9–52.5%), likely reflecting differences in healthcare settings, socioeconomic factors, air pollution exposure levels, and dietary patterns across diverse Chinese regions [52]. South Korean studies similarly showed wide ranges (9.5–33.3%), with community-based cohorts reporting substantially lower prevalence than hospital-based studies. These geographic patterns underscore the importance of considering contextual factors including urbanization, pollution exposure, nutritional status, and healthcare access when interpreting sarcopenia prevalence estimates across Asian populations [53]. Muscle mass assessment methodology represents another potential heterogeneity source, though our data were insufficient for robust subgroup analysis. Studies employing DXA for muscle mass quantification typically reported more precise measurements with narrower confidence intervals compared to BIA-based assessments, consistent with DXA’s superior reproducibility and accuracy [54]. However, both AWGS-2014 and AWGS-2019 consensus explicitly validated both methods for Asian populations, and our subgroup analysis suggested no systematic bias attributable to measurement modality. The choice between DXA and BIA in clinical and research settings typically reflects pragmatic considerations including equipment availability, cost, and patient mobility rather than fundamental methodological superiority for sarcopenia screening [7, 8]. Risk factors and clinical implications Our meta-analysis identified three independent risk factors for sarcopenia in COPD patients, each with distinct clinical implications. The dose-response relationship with age (OR: 1.05 per year) demonstrates that sarcopenia risk increases approximately 5% annually, compounding with each decade of life. In practical terms, a 70-year-old COPD patient has approximately 28% higher sarcopenia risk than a 60-year-old with equivalent disease severity, independent of other factors. This age gradient exceeds that observed in the general elderly population without COPD [55], suggesting synergistic effects between age-related muscle loss (primary sarcopenia) and disease-related muscle wasting (secondary sarcopenia) in COPD [56]. These findings support guideline recommendations for routine sarcopenia screening in elderly COPD patients, particularly those aged ≥ 65 years where age-related and disease-related factors converge to accelerate muscle deterioration [57]. Low body mass index (BMI < 18.5 kg/m²) emerged as the strongest predictor of sarcopenia, with underweight COPD patients demonstrating more than three-fold increased odds (OR: 3.12, 95% CI: 1.98–4.92). This robust association reflects the bidirectional relationship between nutritional status and muscle mass, wherein chronic energy deficiency impairs muscle protein synthesis while muscle wasting further elevates metabolic demands [58]. Notably, the COPD population exhibits a ‘BMI paradox’ wherein moderate overweight (BMI 25–30 kg/m²) associates with improved survival compared to normal weight [59], though this protective effect may reflect preserved muscle mass rather than adiposity per se. Our findings emphasize that BMI assessment alone inadequately captures body composition in COPD; patients with normal or even elevated BMI may harbor significant muscle depletion masked by fat accumulation (sarcopenic obesity) [60]. These observations support integrated assessment strategies combining BMI with direct muscle mass measurement and functional evaluation for comprehensive sarcopenia screening in COPD populations. Severe COPD (GOLD stages 3–4, FEV₁ <50% predicted) demonstrated a nearly three-fold increased sarcopenia risk (OR: 2.74, 95% CI: 1.89–3.97) compared to mild-moderate disease. This strong association reflects multiple converging pathophysiological mechanisms including exercise limitation-induced muscle deconditioning, hypoxemia-driven metabolic dysfunction, systemic inflammation, and increased respiratory work consuming substantial caloric resources [61]. Patients with severe COPD frequently demonstrate quadriceps muscle dysfunction disproportionate to respiratory impairment, with fiber type shifts from oxidative slow-twitch (type I) to glycolytic fast-twitch (type II) fibers, reduced mitochondrial density, and impaired oxidative capacity [10]. These findings support targeted sarcopenia screening in patients with FEV₁ <50% predicted, where early identification and intervention may prevent progressive functional decline and preserve independence [62]. Public health and clinical practice implications The 31% pooled prevalence of sarcopenia in Asian COPD populations carries substantial public health implications. With an estimated 100 million COPD cases in Asia [63], our findings suggest approximately 31 million Asian individuals with COPD may have concurrent sarcopenia, representing a massive burden of disability and healthcare resource utilization. Sarcopenic COPD patients experience 2–3 fold increased hospitalization rates, extended hospital stays, and elevated mortality risk compared to non-sarcopenic counterparts [6], translating to billions of dollars in potentially preventable healthcare expenditures. These projections underscore the urgent need for systematic sarcopenia screening implementation in routine COPD care, particularly in resource-limited Asian settings where disease burden is highest and healthcare systems are often fragmented [64]. Our findings support several specific clinical practice recommendations. First, routine sarcopenia screening should be integrated into comprehensive COPD assessment, particularly for high-risk subgroups including elderly patients (≥ 65 years), those with BMI < 18.5 kg/m² or unintentional weight loss, and individuals with GOLD stage 3–4 disease. Screening can be efficiently implemented using validated questionnaires (e.g., SARC-F, SARC-CalF) [65] followed by objective assessment with handgrip dynamometry and muscle mass measurement via BIA in primary care settings where DXA access is limited. The diagnostic equivalence between AWGS-2014 and AWGS-2019 in COPD populations provides flexibility in criteria selection, allowing clinicians to use either version without substantially affecting case identification [7, 8]. Second, identified sarcopenia should trigger multimodal interventions including resistance exercise training, nutritional supplementation with protein and amino acids, vitamin D optimization, and pulmonary rehabilitation programs specifically incorporating muscle-strengthening components [66]. Randomized controlled trials have demonstrated that combined resistance training and nutritional interventions can increase muscle mass by 1–2 kg and improve functional outcomes in sarcopenic COPD patients over 12–24 weeks [67]. Third, therapeutic decision-making should account for sarcopenia status when considering pharmacological interventions. Corticosteroid minimization strategies become particularly important in sarcopenic patients given the myotoxic effects of chronic glucocorticoid exposure [11]. Emerging pharmacological approaches including selective androgen receptor modulators, myostatin inhibitors, and ghrelin analogs show promise for sarcopenia treatment in COPD, though most remain investigational pending definitive efficacy trials [68]. Fourth, healthcare systems should develop integrated care pathways bridging pulmonology, geriatrics, nutrition, and rehabilitation services to deliver comprehensive sarcopenia management for COPD patients, moving beyond traditional disease-centric models toward holistic patient-centered care addressing multimorbidity [69]. Strengths This systematic review and meta-analysis possesses several notable methodological strengths that enhance the validity and clinical applicability of our findings. First, we employed highly restrictive inclusion criteria requiring exclusive use of AWGS diagnostic criteria (either 2014 or 2019 version), eliminating heterogeneity attributable to diverse diagnostic systems that plagued earlier meta-analyses. This standardization enabled more precise prevalence estimation and facilitated direct comparison between AWGS versions [70]. Second, we explicitly compared AWGS-2014 and AWGS-2019 criteria within the same meta-analysis, providing the first empirical evidence regarding diagnostic equivalence in COPD populations—a critical finding for clinical practice and research synthesis. Third, we conducted comprehensive searches across both Western and Asian-language databases (including CNKI, WanFang, and KoreaMed), substantially reducing language and publication bias risks that disproportionately affect reviews focused on Asian populations [71]. Fourth, all included studies demonstrated high methodological quality (NOS scores 8–10/10), with robust sampling methods, validated outcome assessments, and appropriate statistical analyses, supporting confidence in pooled estimates. Fifth, we employed advanced statistical methods appropriate for prevalence meta-analysis, including Freeman-Tukey double arcsine transformation to handle extreme proportions, REML estimation for between-study variance, and Hartung-Knapp adjustment for conservative confidence interval estimation [34]. Sixth, comprehensive sensitivity analyses confirmed the robustness of our findings to individual study exclusion, methodological choices, and quality thresholds, demonstrating that our conclusions were not driven by any single influential study or analytical decision. Limitations Despite these strengths, several limitations warrant acknowledgment and consideration when interpreting our findings. First, the limited number of included studies overall (n = 10), and particularly those using AWGS-2014 criteria (n = 2), restricted the statistical power for subgroup analyses and meta-regression, precluding definitive assessment of several potentially important moderating variables including sex distribution, COPD phenotypes (emphysema versus chronic bronchitis), smoking status, and comorbidity burden. While our subgroup comparison between AWGS-2014 and AWGS-2019 showed no significant difference, the small number of AWGS-2014 studies limits the certainty of this conclusion, and future studies incorporating both criteria versions within the same cohort would strengthen this finding. The small study number also limits the reliability of publication bias assessment, though Egger’s test (p = 0.596) and funnel plot inspection suggested no significant bias [32]. Second, substantial heterogeneity (I² = 89.9%) persisted despite diagnostic standardization, indicating important unmeasured or uncontrolled sources of variability across studies. While our sensitivity analyses confirmed robust pooled estimates, the wide confidence intervals for individual studies reflect genuine population differences that may limit generalizability to specific clinical contexts. Third, all included studies employed cross-sectional or baseline cohort designs, precluding causal inference regarding temporal relationships between risk factors and sarcopenia development. Longitudinal studies with repeated assessments are needed to distinguish whether identified associations reflect causal pathways versus shared predisposing factors [72]. Fourth, geographic representation was uneven, with multiple studies from China and South Korea but only single studies from India, Thailand, and Malaysia. Large Asian regions including Indonesia, Philippines, Vietnam, Japan, and Central Asian countries were entirely unrepresented, limiting the comprehensiveness of our Asia-wide prevalence estimates. The findings should not be extrapolated uncritically to all Asian populations; the term “Asian” in this context refers specifically to the five countries represented, and conclusions should be applied with caution beyond this geographic scope. Cultural, genetic, dietary, and healthcare system variations across these diverse populations may substantially influence sarcopenia prevalence and risk factor profiles [73]. Fifth, most studies enrolled hospital-based COPD patients, potentially overestimating population-level prevalence due to selection bias toward more severe cases requiring medical attention. Community-based prevalence estimates are needed to establish true population burden and inform public health resource allocation [74]. Sixth, individual patient-level data were unavailable, preventing adjusted analyses controlling for potential confounders or exploration of effect modification by patient characteristics. Future individual participant data meta-analyses could address these limitations and provide more nuanced understanding of sarcopenia heterogeneity in COPD [75]. Finally, our review focused exclusively on sarcopenia prevalence without examining associated clinical outcomes (mortality, hospitalization, quality of life), limiting our ability to quantify the clinical and public health impact of sarcopenia in Asian COPD populations. Future meta-analyses examining outcome data are needed to establish the prognostic significance of sarcopenia in this population and justify resource investment in screening and intervention programs. Future research directions Our findings highlight several critical research gaps requiring urgent attention. First, prospective studies directly comparing AWGS-2014 and AWGS-2019 criteria within the same COPD cohort are needed to definitively establish diagnostic concordance, identify potential misclassification, and determine whether specific COPD subgroups exhibit differential sensitivity to criteria choice. Such studies should assess not only prevalence concordance but also prognostic discrimination and intervention responsiveness using both diagnostic standards [76]. Second, large-scale prospective cohort studies with serial sarcopenia assessments are needed to establish incidence rates, identify trajectories of muscle mass decline, and determine whether interventions can modify disease progression in COPD. Such studies should incorporate comprehensive phenotyping including inflammatory biomarkers, genetic polymorphisms (e.g., ACE, ACTN3, VDR variants associated with muscle mass), metabolomic profiling, and detailed comorbidity assessment to elucidate pathophysiological mechanisms linking COPD and sarcopenia [77]. Third, randomized controlled trials evaluating multimodal interventions (resistance exercise, nutritional supplementation, anabolic agents) specifically in Asian COPD populations are needed, as most efficacy data derive from Western cohorts with potentially different body composition phenotypes and treatment responses [78]. Fourth, studies examining sarcopenia prevalence and outcomes in underrepresented Asian regions (Southeast Asia, Central Asia, South Asia beyond India) would enhance the geographic comprehensiveness of prevalence estimates and identify population-specific risk factors requiring targeted interventions. Fifth, cost-effectiveness analyses evaluating sarcopenia screening strategies in COPD are critically needed to inform policy decisions regarding implementation in resource-limited settings where competing healthcare priorities necessitate evidence-based allocation decisions [79]. Sixth, investigation of novel biomarkers for early sarcopenia detection (e.g., serum creatinine-to-cystatin C ratio, urinary titin fragments, circulating microRNAs) may enable simpler screening approaches suitable for primary care and community settings [80]. Finally, studies examining the impact of emerging COPD therapies including triple inhaler combinations and anti-inflammatory biologics on muscle mass outcomes could reveal whether optimizing respiratory disease control indirectly benefits muscle health through reduced systemic inflammation and improved exercise capacity [81]. Conclusions This systematic review and meta-analysis demonstrates that sarcopenia affects approximately one-third of COPD patients in Asian populations when assessed using standardized AWGS diagnostic criteria, with comparable prevalence estimates between AWGS-2014 (30%) and AWGS-2019 (31%) versions. This diagnostic equivalence in COPD populations represents a novel finding that contrasts with general elderly populations where AWGS-2019 typically identifies fewer cases, and has important implications for clinical screening programs and research synthesis during the transition period between diagnostic standards. The consistency of our findings across diverse Asian populations, study settings, and methodological approaches—coupled with robust sensitivity analyses—supports the validity and clinical relevance of this prevalence estimate. Three modifiable and non-modifiable risk factors (age, BMI, COPD severity) emerged as strong independent predictors of sarcopenia, providing actionable targets for screening prioritization and preventive interventions. The substantial burden of sarcopenia in Asian COPD populations, combined with its well-established adverse effects on functional capacity, quality of life, and mortality, supports implementation of routine sarcopenia screening in clinical practice using either AWGS version, particularly for high-risk subgroups. Multimodal interventions including resistance exercise, nutritional optimization, and pulmonary rehabilitation offer evidence-based approaches to prevent or attenuate muscle wasting and preserve functional independence in this vulnerable population. Healthcare systems should develop integrated care pathways addressing both respiratory and musculoskeletal components of COPD to deliver comprehensive patient-centered management. Future research should prioritize prospective studies directly comparing AWGS versions within COPD cohorts, longitudinal studies establishing sarcopenia incidence and trajectories, intervention trials evaluating prevention and treatment strategies in Asian populations, cost-effectiveness analyses informing policy decisions, and mechanistic studies elucidating pathophysiological pathways amenable to therapeutic targeting. Enhanced recognition of sarcopenia as a critical COPD comorbidity, coupled with systematic screening using validated AWGS criteria and evidence-based interventions, has the potential to substantially improve outcomes and quality of life for millions of Asian individuals living with this debilitating respiratory disease. Supplementary Information Supplementary Material 1. Acknowledgements We thank Dr Nandini Desai, Dean, Shri M.P. Shah Government Medical College, Jamnagar, Gujarat, India, and Dr Dipesh Parmar, Head of the Community Medicine, Shri M.P. Shah Government Medical College, Jamnagar, Gujarat, India, for reviewing our manuscript and giving important comments. Authors’ contributions V.S. and Y.M. were responsible for the conception and design of the study; V.S., Y.M., and H.A. performed data acquisition; Y.M. performed data analyses; V.S. and Y.M. interpreted the results; Y.M. authored the work, and all authors gave it significant revisions before approving the finished draft. Funding All authors have declared that no financial support was received from any organisation for the submitted work. Data availability The datasets generated and/or analysed during the current study are not publicly available to protect the privacy of the study. Still, they are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate This systematic review and meta-analysis were based on previously published studies and did not involve direct human participants, interventions, or collection of primary data. Therefore, ethical approval and individual patient consent were not required. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The datasets generated and/or analysed during the current study are not publicly available to protect the privacy of the study. Still, they are available from the corresponding author upon reasonable request.